Side-by-side · Research reference

EpitalonvsIpamorelin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticDraft8/37 cited

BPhase 1Reviewed21/57 cited

Epitalon

Pineal bioregulator · Telomerase activator

5–10 mgPer cycle doseKhavinson 2003

HumanMechanisticKhavinson 2003

HoursHalf-life (est)

SQ or IM · Abdomen · Daily for 10–20 days

Ipamorelin

Selective GHRP · Ghrelin Mimetic

200–300 mcgPer doseRaun 1998

Phase 1Evidence levelRaun 1998 Sigalos 2018

~2 hrHalf-lifeRaun 1998

SQ · Multiple sites · 1–3×/day

01Mechanism of Action

Parameter

Epitalon

Ipamorelin

Primary target

Telomerase activity (proposed); pineal melatonin axis modulationKhavinson 2003

Ghrelin receptor (GHS-R1a) on anterior pituitaryRaun 1998

Pathway

Activation of telomerase reverse transcriptase (hTERT) in somatic cells; pineal-axis modulation supports endogenous melatoninKhavinson 2003

GHS-R1a binding → Gαq/11 → ↑intracellular Ca²⁺ → GH vesicle exocytosisRaun 1998 Bowers 1991

Downstream effect

Telomere elongation, improved sleep architecture, reported lifespan extension in aged miceKhavinson 2003

GH pulse amplification, IGF-1 elevation, recovery and lipolytic effectsBowers 2002

Feedback intact?

—

Yes — pulsatile pattern preserved; somatostatin feedback activeBowers 2002

Origin

Synthetic 4-AA peptide derived from epithalamin (a natural pineal extract)Khavinson 2003

Pentapeptide H-Aib-His-D-2-Nal-D-Phe-Lys-NH₂; rationally designed for ghrelin-receptor selectivityRaun 1998

Antibody development

—

Not reported in short-term studies

02Dosage Protocols

Parameter

Epitalon

Ipamorelin

Standard dose

5–10 mg / day for 10–20 days, 1–2× per yearKhavinson 2003

Anecdotal community protocol. Russian clinical literature uses similar cycling.

200–300 mcg per injectionRaun 1998

Anecdotal community range; clinical doses 1–3 mg IV in trials.

Frequency

Once daily during a cycle

1–3× per day

Once daily pre-sleep is most common; twice or thrice for advanced users.

Lower / starter dose

2.5 mg / day

100 mcg per dose

Evidence basis

In-vitro telomerase + Russian clinical trialsKhavinson 2003

Phase 1 + clinical practiceRaun 1998 Sigalos 2018

Duration

10–20 day cycles, 1–2× per year

8–12 weeks on / 4 weeks off (anecdotal)

GHS-R desensitisation reported with continuous dosing.

Reconstitution

Bacteriostatic water

Bacteriostatic water; typical 2 mL per 5 mg vial

Timing

Pre-sleep preferred (pineal alignment)

Pre-sleep + fasted preferred; 30 min away from food

Half-life

Hours (estimated)

~2 hoursRaun 1998

Longer than GHRP-6 (15 min); shorter than CJC-1295-DAC (~8 days).

04Side Effects & Safety

Parameter

Epitalon

Ipamorelin

Injection site reaction

Mild irritation

Mild irritation possible

Sleep architecture

Improved subjective sleep quality (anecdotal)

—

Cancer risk

Theoretical via telomerase activation in pre-malignant cells

Theoretical via GH/IGF-1 axis; contraindicated in active malignancy

Long-term safety

Limited Western RCT data

—

Pregnancy / OB

Avoid

Antibody formation

Not reported

—

Cortisol elevation

—

Negligible vs other GHRPsRaun 1998

Prolactin elevation

—

NegligibleRaun 1998

Hunger

—

Mild appetite increase via ghrelin-receptor crosstalk

GH excess (overdose)

—

Joint pain, edema, insulin resistance

IGF-1 elevation

—

Dose-dependent; monitor with chronic high-dose use

Absolute Contraindications

Epitalon

·Pregnancy / breastfeeding
·Active malignancy or pre-malignant state

Ipamorelin

·Active malignancy or cancer history
·Pregnancy / breastfeeding
·Disrupted hypothalamic-pituitary axis

Relative Contraindications

Epitalon

·Family history of cancer

Ipamorelin

·Untreated diabetes
·Severe insulin resistance
·Concurrent corticosteroid use (theoretical desensitisation)

05Administration Protocol

Parameter

Epitalon

Ipamorelin

1. Reconstitution

Add 1–2 mL bacteriostatic water to 10 mg vial → 5–10 mg/mL.

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL. Roll gently. Solution should be clear.

2. Injection site

SQ — abdomen preferred. Rotate sites.

Subcutaneous, abdomen or thigh. Rotate sites. Pinch fat for shallow SQ delivery.

3. Timing

Pre-sleep preferred to align with pineal axis.

Pre-sleep optimal — aligns with natural GH pulse. Some protocols add a morning fasted dose.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

Lyophilised: room temp, protected from light. Reconstituted: refrigerate 2–8 °C, use within 30 days.

5. Needle

29–31G, 4–8 mm insulin syringe.

06Stack Synergy

Epitalon

— no documented stacks

Ipamorelin

+ Tesamorelin

Strong

View Tesamorelin →

Ipamorelin (GHRP) + tesamorelin (GHRH analogue) is the textbook dual-axis GH stack. They activate two distinct pituitary receptors — the ghrelin receptor and the GHRH receptor — producing a synergistic GH pulse larger than either alone. Ipamorelin's selectivity (no cortisol/prolactin spike) makes it the ideal GHRP partner for long-term protocols.

Ipamorelin: 200–300 mcg SQ · pre-sleep
Tesamorelin: 2 mg SQ · same injection · pre-sleep
Primary benefit: Maximal GH pulsatility, fat loss, recovery, sleep depth

Raun 1998 Bowers 2002

+ CJC-1295 (no DAC)

Strong

View CJC-1295 (no DAC) →

CJC-1295 (no DAC) is a short-acting GHRH analogue. Combined with ipamorelin (GHRP), the pulse is amplified across both receptor systems with timing similar to native physiology. Without the DAC modification, the stack maintains sharp peaks rather than the sustained elevation seen with CJC-1295-DAC + ipamorelin.

Ipamorelin: 200–300 mcg SQ · pre-sleep
CJC-1295 (no DAC): 100 mcg SQ · same injection
Primary benefit: Pulsatile GH stimulation matching physiological pattern

Teichman 2006 Ionescu 2006